Curaleaf Stock Surges Nearly 10% on CBD Study Breakthrough
Curaleaf shares soared nearly 10% Thursday after researchers uncovered potential new therapeutic applications for cannabidiol. A University of California study funded by the National Institute on Alcohol Abuse and Alcoholism demonstrated CBD's efficacy in reducing withdrawal symptoms and relapse rates in rodent models of alcoholism.
The findings, published in Nature, mark a significant development for non-psychoactive cannabis compounds. Federal involvement in the research suggests growing institutional recognition of CBD's medical potential, though the study remains in preclinical stages. Market reaction highlights investor enthusiasm for cannabis stocks with legitimate therapeutic pipelines.